---
title: "Sector Update: Health Care Stocks Decline Monday Afternoon"
description: "Health care stocks declined on Monday, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. Novo Nordisk shares fell 9% following disappointing trial "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231259350.md"
published_at: "2025-03-10T18:02:51.000Z"
---

# Sector Update: Health Care Stocks Decline Monday Afternoon

> Health care stocks declined on Monday, with the NYSE Health Care Index down 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. Novo Nordisk shares fell 9% following disappointing trial results for its weight loss drug. In contrast, Checkpoint Therapeutics shares surged nearly 62% after announcing an acquisition by Sun Pharmaceutical. BioNTech's shares dropped 2.6% after reporting a decline in Q4 revenue and projecting further sales decreases in 2025.

Health care stocks were lower Monday afternoon, with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%.

The iShares Biotechnology ETF (IBB) retreated 0.1%.

In corporate news, Novo Nordisk shares fell 9% after the latest trial results of the Danish drugmaker's investigative weight loss drug, CagriSema, trailed its own initial expectations.

Checkpoint Therapeutics shares were rising nearly 62% after the firm and India's Sun Pharmaceutical said Sunday that Checkpoint has agreed to be acquired by Sun for $4.10 a share in cash plus a non-transferable contingent value right.

BioNTech reported a decline in Q4 revenue and projected full-year sales to fall again in 2025. Its shares fell 2.6%.

### Related Stocks

- [BNTX.US - BioNTech SE](https://longbridge.com/en/quote/BNTX.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/en/news/276447697.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/en/news/276440991.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/en/news/276442777.md) |
| Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO | Savvy Advisors Inc. increased its stake in Novo Nordisk A/S by 83.0% in Q3, acquiring 22,138 shares, bringing its total  | [Link](https://longbridge.com/en/news/275761183.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.